loader
Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Cemiplimab reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Cemiplimab

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 8Libtayo

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Libtayo

    France
    arrow
    CPhI Worldwide, Milan
    Attending
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Cemiplimab-rwlc

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 81

    2019 Revenue in Millions : 213

    Growth (%) : -62

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Libtayo

    France
    arrow
    CPhI Worldwide, Milan
    Attending
    Contact Supplier Contact Supplier
    Flag France
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

    Sanofi

    Cemiplimab-rwlc

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 142

    2020 Revenue in Millions : 73

    Growth (%) : 93

    Sanofi Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Libtayo

    cemiplimab-rwlc

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Libtayo

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Regeneron

    cemiplimab-rwlc

    Main Therapeutic Indication : Oncology

    Currency : USD

    2019 Revenue in Millions : 176

    2018 Revenue in Millions : 15

    Growth (%) : 1,087

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Libtayo

    Cemiplimab-rwlc

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Libtayo

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Regeneron

    Cemiplimab-rwlc

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 271

    2019 Revenue in Millions : 176

    Growth (%) : 54

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Libtayo

    Cemiplimab-rwlc

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Libtayo

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Regeneron

    Cemiplimab-rwlc

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 306

    2020 Revenue in Millions : 271

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Libtayo

    Cemiplimab-rwlc

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Libtayo

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Regeneron

    Cemiplimab-rwlc

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 448

    2021 Revenue in Millions : 306

    Growth (%) : 46

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Libtayo

    Cemiplimab-rwlc

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Libtayo

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Regeneron

    Cemiplimab-rwlc

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 863

    2022 Revenue in Millions : 448

    Growth (%) : 93

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Libtayo

    Cemiplimab-Rwlc

    arrow
    Luxepack
    Not Confirmed

    Brand Name : Libtayo

    U.S.A
    arrow
    Luxepack
    Not Confirmed

    Regeneron

    Cemiplimab-Rwlc

    Main Therapeutic Indication : Oncology

    Currency : USD

    2018 Revenue in Millions : 15

    2017 Revenue in Millions : 0

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF